• About
    • About Us
    • Our Team
    • Resources
    • Prader-Willi Syndrome
    • News & Presentations
  • Developments
    • EPM301
    • Future Developments
  • Investors
  • Contact

Get in touch

(859) 648-3367

letstalk@epmtherapeutics.com

Yellow hexagon with flower design next to the letters
EPM Therapeutics Business Logo with Yellow Hexagon and Flower Design
  • About
    • About Us
    • Our Team
    • Resources
    • Prader-Willi Syndrome
    • News & Presentations
  • Developments
    • EPM301
    • Future Developments
  • Investors
  • Contact

epm Therapeutics Secures FDA Pre-IND Meeting to Advance EPM301 for Prader-Willi Syndrome

10 January 2026
epm Therapeutics Secures FDA Pre-IND Meeting to Advance EPM301 for Prader-Willi Syndrome
epm Therapeutics Secures FDA Pre-IND Meeting to Advance EPM301 for Prader-Willi Syndrome
Download PDF
< Older Post

Comprehensive Therapeutic Potential of EPM301 for Hyperphagia, Anxiety, and Sleep Disturbances in Prader-Willi Syndrome

by EPM Therapeutics • 8 December 2025

Preclinical Findings Suggest That EPM301 Could Offer Multiple Benefits As A Novel Treatment For Symptoms of Prader-Willi Syndrome

by EPM Therapeutics • 8 December 2025
Light yellow background with glowing white hexagon shapes.

Enhanced Bioavailability and Therapeutic Potential of EPM301, a Novel Cannabidiol Analogue, in the treatment of Prader-Willi Syndrome

by EPM Therapeutics • 5 June 2025
EPM Therapeutics Business Logo with Yellow Hexagon and Flower Design

Contact Us

(859) 648-3367 Send A Message

Quick Links

Investor Hub

EPM301

About Us

Resources

© 2026 

All Rights Reserved | EPM Group Inc. dba epm Therapeutics

Accessibility Statement | Privacy Policy

Website by Creekmore Marketing

Share by: